The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site.

OncoFAP-based pro-drugs are currently being developed for the imaging and therapy of cancer.